Results 31 to 40 of about 43,769 (228)

Neuraminidase-1 contributes significantly to the degradation of neuronal B-series gangliosides but not to the bypass of the catabolic block in Tay–Sachs mouse models

Molecular Genetics and Metabolism Reports, 2015
Tay–Sachs disease is a severe lysosomal storage disorder caused by mutations in the HEXA gene coding for α subunit of lysosomal β-Hexosaminidase A enzyme, which converts GM2 to GM3 ganglioside. HexA−/− mice, depleted of the β-Hexosaminidase A iso-enzyme,
Z.K. Timur, S. Akyildiz Demir, C. Marsching, R. Sandhoff, V. Seyrantepe   +4 more
doaj   +1 more source

Influenza neuraminidase mutations and resistance to neuraminidase inhibitors

Emerging Microbes & Infections
Mutations in influenza virus neuraminidase (NA) can lead to viral resistance to NA inhibitors (NAIs). To update global influenza NA mutations and resistance to NAIs, we investigated epidemic information from global regions for NAIs-resistant influenza strains and analyzed their NA mutations.
Jiapeng Xu, Qiting Luo, Yuanyuan Huang, Jieyu Li, Wei Ye, Ran Yan, Xinrui Zhou, Zhendan He, Ge Liu, Qinchang Zhu   +9 more
openaire   +3 more sources

Neuraminidase B controls neuraminidase A-dependent mucus production and evasion [PDF]

PLOS Pathogens, 2020
AbstractBinding ofStreptococcus pneumoniae(Spn) to nasal mucus leads to entrapment and clearance via mucociliary activity during colonization. To identify Spn factors allowing for evasion of mucus binding, we used a solid-phase adherence assay with immobilized mucus of human and murine origin.
Alexandria J Hammond, Ulrike Binsker, Surya D Aggarwal, Mila Brum Ortigoza, Mila Brum Ortigoza, Cynthia Loomis, Jeffrey N Weiser   +6 more
openaire   +5 more sources

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin

mBio, 2017
Antibody responses to influenza virus hemagglutinin provide protection against infection and are well studied. Less is known about the human antibody responses to the second surface glycoprotein, neuraminidase. Here, we assessed human antibody reactivity
Madhusudan Rajendran, Raffael Nachbagauer, Megan E. Ermler, Paul Bunduc, Fatima Amanat, Ruvim Izikson, Manon Cox, Peter Palese, Maryna Eichelberger, Florian Krammer   +9 more
doaj   +1 more source

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

Advanced Healthcare Materials, EarlyView.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee, Khulan Nyamzaya, Jueun Han, Yejin Song, Jihee Lee, Jung Hyun Jo, Seungmin Bang, Eun‐Kyung Lim, Seungjoo Haam, Eunjung Kim   +9 more
wiley   +1 more source

Influenza’s Newest Trick

mBio, 2019
Influenza A viruses are important pathogens for humans and for many birds and mammals. Hemagglutinin and neuraminidase are the major surface proteins of this enveloped RNA virus. Hemagglutinin requires proteolytic cleavage for activation, but because the
Jeffery K. Taubenberger
doaj   +1 more source

Antiviral effects and mechanism of Qi pi pill against influenza viruses

Animal Models and Experimental Medicine, EarlyView.
Qi pi pill presents anti‐influenza effect and inhibits viral replication in vitro by targeting both the viral RNA replication and the release of new viral particles. Furthermore, QPP modulates the production of proinflammatory cytokines induced by influenza infection in host cells.
Chengcheng Zhang, Jing Gao, Meiyue Dong, Carolina Q. Sacramento, Ping Li, Xiangyu Lian, Lingyuan Fan, Lijun Rong, Ruikun Du, Jingzhen Tian, Qinghua Cui   +10 more
wiley   +1 more source

Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges

Animal Models and Experimental Medicine, EarlyView.
Abstract Respiratory infectious diseases frequently erupt on a global scale, with RNA viruses, such as SARS‐CoV‐2, RSV, and influenza viruses, posing challenges to vaccine development due to their high mutation rates. Traditional vaccine development cycles are lengthy and struggle to keep pace with rapidly evolving viruses, whereas messenger RNA (mRNA)
Linlin Zheng, Han Feng
wiley   +1 more source

Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design [PDF]

Scientific Reports, 2015
AbstractNeuraminidase (NA) inhibitors are the dominant antiviral drugs for treating influenza in the clinic. Increasing prevalence of drug resistance makes the discovery of new NA inhibitors a high priority. Thirty-one triterpenoids from the medicinal mushroom Ganoderma lingzhi were analyzed in an in vitro NA inhibition assay, leading to the discovery ...
Qinchang Zhu, Koichiro Ohnuki, Kuniyoshi Shimizu, Takashi Sawai, Tran Hai Bang, Ken Sawai   +5 more
openaire   +3 more sources

Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection

Viruses, 2022
Avian influenza virus remains a threat for humans, and vaccines preventing both avian and human influenza virus infections are needed. Since virus-like particles (VLPs) expressing single neuraminidase (NA) subtype elicited limited heterosubtypic ...
Hae-Ji Kang, Ki-Back Chu, Keon-Woong Yoon, Gi-Deok Eom, Jie Mao, Min-Ju Kim, Su-Hwa Lee, Eun-Kyung Moon, Fu-Shi Quan   +8 more
doaj   +1 more source